Earnings History Data for Arrowhead Pharmaceuticals, Inc. (ARWR) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
10-02-2025	AH		ARWR	Arrowhead Pharmaceuticals, Inc.	2,550	-1.39	-0.42	-1.24	Arrowhead Pharmaceuticals GAAP EPS of -$1.39 misses by $1.01, revenue of $2.5M misses by $16.55M [2/10/2025 4:03 PM]	18.91	-1.01 (-5.05%)	18.60	-1.32 (-6.63%)	17.05 - 36.72	1,464,578	1,370,000	5,034
Arrowhead Pharmaceuticals GAAP EPS of -$1.39 misses by $1.01, revenue of $2.5M misses by $16.55M [2/10/2025 4:03 PM] Arrowhead sees potential $2-3B annual sales for plozasiran in SHTG market by 2026 [2/10/2025 9:36 PM] Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics [2025-02-10 08:30AM] Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results [2025-02-10 04:01PM] Arrowhead Research: Fiscal Q1 Earnings Snapshot [2025-02-10 04:08PM] Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... [2025-02-11 02:06AM] Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call [2025-02-11 10:10AM]
26-11-2024	AH		ARWR	Arrowhead Pharmaceuticals, Inc.	2,270	-1.38	-0.63	-1.03	Arrowhead Pharmaceuticals GAAP EPS of -$5.00 misses by $0.48, revenue of $3.55M [11/26/2024 4:06 PM]	26.17	5.12 (24.32%)	22.13	1.08 (5.13%)	17.05 - 39.83	6,248,599	1,850,000	25,024
Arrowhead climbs after licensing deal with Sarepta [11/26/2024 8:07 AM] Arrowhead Pharmaceuticals GAAP EPS of -$5.00 misses by $0.48, revenue of $3.55M [11/26/2024 4:06 PM] Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs [2024-11-26 07:00AM] Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs [2024-11-26 07:00AM] Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta [2024-11-26 09:06AM] Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal [2024-11-26 10:55AM] Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results [2024-11-26 04:00PM] Arrowhead Pharma, Sarepta TX ink new gene therapy deal [2024-11-26 04:05PM] Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ... [2024-11-27 02:04AM] Arrowhead and Sarepta link for rare genetic disease treatments [2024-11-27 04:33AM] Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments [2024-11-27 07:21AM] Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board [2024-11-27 07:20AM] Arrowhead Stock Rockets 16% After Major Licensing Deal [2024-11-27 11:07AM] Q4 2024 Arrowhead Pharmaceuticals Inc Earnings Call [2024-11-27 12:40PM]
08-08-2024	AH		ARWR	Arrowhead Pharmaceuticals, Inc.	3,210	-1.38	-0.58	-0.96	Arrowhead Pharmaceuticals GAAP EPS of -$1.38 misses by $0.81 [8/8/2024 4:21 PM]	23.39	-2.46 (-9.52%)	25.00	-0.85 (-3.29%)	20.67 - 39.83	1,645,371	970,000	2,820
Arrowhead Pharmaceuticals GAAP EPS of -$1.38 misses by $0.81 [8/8/2024 4:21 PM] Arrowhead Pharmaceuticals announces $500M strategic financing facility with Sixth Street [8/8/2024 4:24 PM]
09-05-2024	AH		ARWR	Arrowhead Pharmaceuticals, Inc.	3,100	-1.02	-0.06	0.45	Arrowhead Pharmaceuticals GAAP EPS of -$1.02 misses by $0.80 [5/9/2024 4:01 PM]	22.00	-2.72 (-11.02%)	24.30	-0.42 (-1.70%)	20.67 - 41.28	2,279,856	820,000	50,009
Arrowhead Pharmaceuticals GAAP EPS of -$1.02 misses by $0.80 [5/9/2024 4:01 PM]
06-02-2024	AH		ARWR	Arrowhead Pharmaceuticals, Inc.	3,960	-1.24	-0.78	-0.39	Arrowhead Pharmaceuticals GAAP EPS of -$1.24 misses by $0.43, revenue of $3.55M misses by $26.09M [2/6/2024 4:24 PM]	31.57	-1.64 (-4.92%)	31.20	-2.00 (-6.02%)	20.67 - 42.48	2,761,243	810,000	3,781
Arrowhead Pharmaceuticals GAAP EPS of -$1.24 misses by $0.43, revenue of $3.55M misses by $26.09M [2/6/2024 4:24 PM] Arrowhead stock slides 6% as fiscal Q1 report falls short of estimates [2/6/2024 4:57 PM]
29-11-2023	AH		ARWR	Arrowhead Pharmaceuticals, Inc.	3,080	-1.03	-0.70	-0.81	Arrowhead Pharmaceuticals GAAP EPS of -$1.92 misses by $0.41, revenue of $240.73M misses by $22.85M [11/29/2023 4:04 PM]	21.22	-7.76 (-26.78%)	28.01	-0.97 (-3.35%)	21.22 - 42.48	5,176,503	850,000	2,878
Arrowhead Pharmaceuticals GAAP EPS of -$1.92 misses by $0.41, revenue of $240.73M misses by $22.85M [11/29/2023 4:04 PM]
07-08-2023	AH		ARWR	Arrowhead Pharmaceuticals, Inc.	3,460	-0.96	-0.58	-0.68	Arrowhead Pharmaceuticals GAAP EPS of -$0.96 misses by $0.37, revenue of $15.83M misses by $29.59M [8/7/2023 4:40 PM]	27.52	-3.29 (-10.66%)	29.85	-0.96 (-3.12%)	23.09 - 48.48	2,163,628	820,000	6,863
Arrowhead Pharmaceuticals GAAP EPS of -$0.96 misses by $0.37, revenue of $15.83M misses by $29.59M [8/7/2023 4:40 PM]
02-05-2023	AH	4:00 PM ET (May 2)	ARWR	Arrowhead Pharmaceuticals, Inc.	3,790	0.45	-0.65	0.41	Arrowhead Pharmaceuticals GAAP EPS of $0.45 beats by $1.06, revenue of $146.26M beats by $100.78M [5/2/2023 5:04 PM]	40.17	4.79 (13.54%)	38.47	3.09 (8.73%)	23.09 - 48.48	2,059,030	1,240,000	12,595
Arrowhead Pharmaceuticals GAAP EPS of $0.45 beats by $1.06, revenue of $146.26M beats by $100.78M [5/2/2023 5:04 PM]
06-02-2023	AH	4:00 PM ET (Feb 6)	ARWR	Arrowhead Pharmaceuticals, Inc.	3,950	-0.39	1.14	-0.60	Arrowhead Pharmaceuticals EPS of -$0.39, revenue of $62.55M [2/6/2023 4:03 PM]	33.54	0.03 (0.09%)	33.25	-0.26 (-0.78%)	26.81 - 56.25	1,198,523	800,000	3,276
Arrowhead drops as Cantor flags risks to Johnson & Johnson licensing deal [2/6/2023 2:49 PM] Arrowhead Pharmaceuticals EPS of -$0.39, revenue of $62.55M [2/6/2023 4:03 PM] Arrowhead Pharmaceuticals' fiscal 2023 Q1 revenue surge helped by milestone payments [2/6/2023 6:02 PM]
28-11-2022	AH	4:00 PM ET (Nov 28)	ARWR	Arrowhead Pharmaceuticals, Inc.	3,110	-0.81	-0.56	-0.61	Arrowhead Pharmaceuticals GAAP EPS of -$1.67 misses by $0.70, revenue of $243.23M misses by $50.38M [11/28/2022 4:05 PM]	29.94	1.94 (6.93%)	26.75	-1.25 (-4.46%)	26.81 - 74.77	1,466,872	780,000	6,259
Arrowhead Pharmaceuticals GAAP EPS of -$1.67 misses by $0.70, revenue of $243.23M misses by $50.38M [11/28/2022 4:05 PM] Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results [Nov-28-22 04:00PM] Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease [Nov-29-22 12:01PM] Edited Transcript of ARWR.OQ earnings conference call or presentation 28-Nov-22 9:30pm GMT [Nov-28-22 04:30PM]
04-08-2022	AH	4:00 PM ET (Aug 4)	ARWR	Arrowhead Pharmaceuticals, Inc.	4,510	-0.68	-0.45	-0.29	Arrowhead Pharmaceuticals GAAP EPS of -$0.68 misses by $0.21, revenue of $32.41M misses by $20.2M [8/4/2022 4:32 PM]	46.00	-0.13 (-0.28%)	44.00	-2.13 (-4.62%)	26.81 - 84.83	1,072,765	720,000	562
Arrowhead Pharmaceuticals GAAP EPS of -$0.68 misses by $0.21, revenue of $32.41M misses by $20.2M [8/4/2022 4:32 PM] Arrowhead Pharmaceuticals (ARWR) Q3 2022 Earnings Call Transcript [Aug-05-22 12:00AM] Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results [Aug-04-22 04:00PM]
10-05-2022	AH	4:00 PM ET (May 10)	ARWR	Arrowhead Pharmaceuticals, Inc.	3,890	0.41	0.39	-0.26	Arrowhead Pharmaceuticals GAAP EPS of $0.41 beats by $0.12, revenue of $151.8M beats by $29.65M [5/10/2022 4:01 PM]	28.89	-5.40 (-15.75%)	35.93	1.64 (4.78%)	28.53 - 93.66	1,681,010	880,000	2,345
Arrowhead Pharmaceuticals GAAP EPS of $0.41 beats by $0.12, revenue of $151.8M beats by $29.65M [5/10/2022 4:01 PM] Arrowhead Pharma down 12% despite quarterly beats, swing to net gain [5/11/2022 2:12 PM] Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives [May-09-22 10:30AM] Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results [May-10-22 04:00PM]
02-02-2022	AH	4:00 PM ET (Feb 2)	ARWR	Arrowhead Pharmaceuticals, Inc.	5,280	-0.60	-0.22	-0.20	Arrowhead Pharmaceuticals GAAP EPS of -$0.60 misses by $0.20, revenue of $27.4M misses by $23.64M [2/2/2022 4:10 PM]	49.14	-3.49 (-6.63%)	49.00	-3.63 (-6.90%)	46.68 - 93.66	945,723	790,000	6,834
Arrowhead Pharmaceuticals GAAP EPS of -$0.60 misses by $0.20, revenue of $27.4M misses by $23.64M [2/2/2022 4:10 PM] Arrowhead down 4% after hours amid big earnings miss on both top and bottom lines [2/2/2022 5:46 PM] Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results [Feb-02-22 04:00PM]
22-11-2021	AH	4:00 PM ET (Nov 22)	ARWR	Arrowhead Pharmaceuticals, Inc.	7,380	-0.61	0.04	-0.48	Arrowhead Pharmaceuticals EPS misses by $0.77, misses on revenue [11/22/2021 4:03 PM]	70.80	1.52 (2.19%)	69.41	0.13 (0.19%)	56.05 - 93.66	792,591	810,000	2,403
Arrowhead Pharmaceuticals EPS misses by $0.77, misses on revenue [11/22/2021 4:03 PM] Arrowhead in up to $1B licensing deal with GSK for RNAi candidate [11/22/2021 4:47 PM] Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results [Nov-22-21 04:01PM] Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD [Nov-22-21 04:00PM] GSK ties up with Arrowhead to develop NASH drug candidate [Nov-22-21 04:02PM] 4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout [Nov-23-21 06:23AM]
05-08-2021	AH	4:00 PM ET (Aug 5)	ARWR	Arrowhead Pharmaceuticals, Inc.	6,950	-0.29	-0.08	-0.13	Arrowhead Pharmaceuticals EPS misses by $0.20, beats on revenue [8/5/2021 4:02 PM]	64.75	-3.30 (-4.85%)	67.50	-0.55 (-0.81%)	32.86 - 93.66	1,043,348	600,000	1,782
Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results [Aug-05-21 04:00PM] Arrowhead Pharmaceuticals, inc (ARWR) Q3 2021 Earnings Call Transcript [Aug-06-21 02:01AM]
04-05-2021	AH	4:00 PM ET (May 4)	ARWR	Arrowhead Pharmaceuticals, Inc.	7,860	-0.26	-0.09	-0.20	Arrowhead Pharmaceuticals EPS misses by $0.16, misses on revenue [5/4/2021 4:01 PM]	66.54	0.06 (0.09%)	66.50	0.02 (0.03%)	30.83 - 92.60	807,436	680,000	1,475
Arrowhead Pharmaceuticals EPS misses by $0.16, misses on revenue [5/4/2021 4:01 PM] Is Arrowhead Pharmaceuticals (ARWR) A Smart Long-Term Buy? [May-03-21 12:53PM] Arrowhead Pharmaceuticals, Inc. to Host Earnings Call [May-04-21 02:30PM] Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results [May-04-21 04:00PM] Arrowhead Pharmaceuticals, Inc (ARWR) Q2 2021 Earnings Call Transcript [May-05-21 02:01AM]
04-02-2021	AH	4:00 PM ET (Feb 4)	ARWR	Arrowhead Pharmaceuticals, Inc.	8,360	-0.20	1.00	-0.03	Arrowhead Pharmaceuticals EPS beats by $0.04, misses on revenue [2/4/2021 4:01 PM]	90.54	6.62 (7.89%)	81.94	-1.98 (-2.36%)	19.51 - 91.70	1,374,705	765,620	3,022
Arrowhead Pharmaceuticals EPS beats by $0.04, misses on revenue [2/4/2021 4:01 PM] Arrowhead Pharmaceuticals: Q1 Earnings Insights [Feb-04-21 05:31PM] Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results [Feb-04-21 04:00PM] Arrowhead Pharmaceuticals, Inc. to Host Earnings Call [Feb-04-21 02:45PM]
23-11-2020	AH	4:00 PM ET (Nov 23)	ARWR	Arrowhead Pharmaceuticals, Inc.	7,050	-0.48	0.34	0.11	Arrowhead Pharmaceuticals EPS of -$0.84 [11/23/2020 4:18 PM]	60.27	-7.93 (-11.63%)	65.46	-2.74 (-4.02%)	19.51 - 73.72	3,337,809	929,134	2,688
Arrowhead Pharmaceuticals EPS of -$0.84 [11/23/2020 4:18 PM]
05-08-2020	AH	4:00 PM ET (Aug 5)	ARWR	Arrowhead Pharmaceuticals, Inc.	4,380	-0.13	-0.07	0.21	Arrowhead Pharmaceuticals EPS beats by $0.04, misses on revenue [8/5/2020 4:01 PM]	41.29	-2.27 (-5.21%)	43.60	0.04 (0.09%)	19.51 - 73.72	604,856	783,530	3,217